# Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia

> **NCT01657955** · PHASE3 · UNKNOWN · sponsor: **Shandong Lanjin Pharmaceuticals Co.,Ltd** · enrollment: 96 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Leukemia
- Neoplasms

## Interventions

- **DRUG:** Bendamustine Hydrochloride Injection
- **DRUG:** Chlorambucil

## Key facts

- **NCT ID:** NCT01657955
- **Lead sponsor:** Shandong Lanjin Pharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-01
- **Primary completion:** 2013-10
- **Final completion:** 2013-12
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2012-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01657955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01657955, "Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT01657955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*